BioSpace News Archive

VectorY Therapeutics today announces participation in three upcoming conferences.

Annovis Bio, Inc. announced today that the U.S. Food and Drug Administration (FDA) has authorized the Phase 2/3 clinical study of buntanetap in moderate Alzheimer’s Disease (AD).

Celularity Inc., a clinical-stage biotechnology company developing placenta-derived allogeneic cell therapies, announced the promotion of two senior executives and the formation of a new Executive Committee.

Enzo Biochem, Inc., a leading biosciences and diagnostics company, announced the official launch of the Company’s new 100,000 square foot state-of-the-art laboratory and research facilities in Farmingdale, New York.

Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Company will present at two important conferences this month.

Cytovia Therapeutics, Inc., a biopharmaceutical company empowering natural killer (NK) cells to fight cancer through stem cell engineering and multispecific antibodies, announced today that it will be presenting new preclinical data for its TALEN® gene-edited, iPSC-derived NK cells and GPC3-targeted Flex-NK™ cell engager antibodies at the Society for Immunotherapy of Cancer’s 37th Annual Meeting.

Juno Diagnostics, a company focused on bringing vital health information to patients by improving access, affordability and transparency, announced the appointment of Todd Whitson as Executive Vice President, Global Business Development and Commercial Operations.

Ro, the leading direct-to-patient healthcare company, today, announced an agreement with the National Institute on Aging (NIA), part of the National Institutes of Health (NIH), to create the “Registry for Equal Access to Clinical Trials in Alzheimer’s Disease (AD)” (REACT-AD).

Seagen Inc. (Nasdaq: SGEN) today announced that it will report its third quarter 2022 financial results on Thursday, October 27, 2022 after the close of U.S. financial markets.

Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced it will present data from DRAGON, a Phase 1 proof-of-concept study of SRK-181 in patients with advanced solid tumors.